MicroRNA-205, a novel regulator of the anti-apoptotic protein Bcl2, is downregulated in prostate cancer

Verdoodt,Berlinda; Neid,Matthias; Vogt,Markus; Kuhn,Viktoria; Liffers,Sven-Thorsten; Palisaar,Rein-Jüri; Noldus,Joachim; Tannapfel,Andrea; Mirmohammadsadegh,Alireza

doi:10.3892/ijo.2013.1915

MicroRNA-205, a novel regulator of the anti-apoptotic protein Bcl2, is downregulated in prostate cancer

Authors:
- Berlinda Verdoodt
- Matthias Neid
- Markus Vogt
- Viktoria Kuhn
- Sven-Thorsten Liffers
- Rein-Jüri Palisaar
- Joachim Noldus
- Andrea Tannapfel
- Alireza Mirmohammadsadegh
View Affiliations

Affiliations: Institute of Pathology, Ruhr-University Bochum, D-44789 Bochum, Germany, Department of Urology, Marienhospital Herne, Ruhr-University Bochum, D-44627 Herne, Germany
Published online on: April 23, 2013 https://doi.org/10.3892/ijo.2013.1915
Pages: 307-314

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Decreased expression of the microRNA miR-205 has been observed in multiple tumour types due to its role in the epithelial to mesenchymal transition, which promotes metastasis. We determined the expression of miR-205 in 111 archival samples of prostate carcinoma and found it to be strongly reduced in most samples, with a median expression level of 16% in comparison to benign tissue from the same patient. Lower miR-205 expression correlated significantly with tumour size and miR-205 levels decreased with increasing Gleason score from 7a=3+4 to 8=4+4. In addition, we describe the anti-apoptotic protein BCL2 as a target of miR-205, relevant for prostate cancer due to its role in prognosis of primary tumours and in the appearance of androgen independence. The repression of BCL2 by miR-205 was confirmed using reporter assays and western blotting. BCL2 mRNA expression in the same collective of prostate cancer tissue samples was associated with higher Gleason score and extracapsular extension of the tumour (pT3). Consistent with its anti-apoptotic target BCL2, miR-205 promoted apoptosis in prostate cancer cells in response to DNA damage by cisplatin and doxorubicin in the prostate cancer cell lines PC3 and LnCap. MiR-205 also inhibited proliferation in these cell lines.

View Figures

View References

1.	Gregory PA, Bracken CP, Bert AG and Goodall GJ: MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle. 7:3112–3118. 2008. View Article : Google Scholar : PubMed/NCBI
2.	Puhr M, Hoefer J, Schafer G, et al: Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Am J Pathol. 181:2188–2201. 2012. View Article : Google Scholar : PubMed/NCBI
3.	Sempere LF, Christensen M, Silahtaroglu A, et al: Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res. 67:11612–11620. 2007. View Article : Google Scholar : PubMed/NCBI
4.	Childs G, Fazzari M, Kung G, et al: Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. Am J Pathol. 174:736–745. 2009. View Article : Google Scholar : PubMed/NCBI
5.	Wiklund ED, Bramsen JB, Hulf T, et al: Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer. 128:1327–1334. 2011. View Article : Google Scholar : PubMed/NCBI
6.	Coppola V, De Maria R and Bonci D: MicroRNAs and prostate cancer. Endocr Relat Cancer. 17:F1–F17. 2010. View Article : Google Scholar : PubMed/NCBI
7.	Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL and Visakorpi T: MicroRNA expression profiling in prostate cancer. Cancer Res. 67:6130–6135. 2007. View Article : Google Scholar : PubMed/NCBI
8.	Schaefer A, Jung M, Mollenkopf HJ, et al: Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer. 126:1166–1176. 2010.PubMed/NCBI
9.	Chung TK, Cheung TH, Huen NY, et al: Dysregulated microRNAs and their predicted targets associated with endometrioid endometrial adenocarcinoma in Hong Kong women. Int J Cancer. 124:1358–1365. 2009. View Article : Google Scholar
10.	Karaayvaz M, Zhang C, Liang S, Shroyer KR and Ju J: Prognostic significance of miR-205 in endometrial cancer. PLoS One. 7:e351582012. View Article : Google Scholar : PubMed/NCBI
11.	Matsushima K, Isomoto H, Yamaguchi N, et al: MiRNA-205 modulates cellular invasion and migration via regulating zinc finger E-box binding homeobox 2 expression in esophageal squamous cell carcinoma cells. J Transl Med. 9:302011. View Article : Google Scholar : PubMed/NCBI
12.	Markou A, Tsaroucha EG, Kaklamanis L, Fotinou M, Georgoulias V and Lianidou ES: Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem. 54:1696–1704. 2008. View Article : Google Scholar : PubMed/NCBI
13.	Wu H, Zhu S and Mo YY: Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res. 19:439–448. 2009. View Article : Google Scholar : PubMed/NCBI
14.	Dar AA, Majid S, de Semir D, Nosrati M, Bezrookove V and Kashani-Sabet M: miRNA-205 suppresses melanoma cell proliferation and induces senescence via regulation of E2F1 protein. J Biol Chem. 286:16606–16614. 2011. View Article : Google Scholar : PubMed/NCBI
15.	Piovan C, Palmieri D, Di Leva G, et al: Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer. Mol Oncol. 6:458–472. 2012. View Article : Google Scholar : PubMed/NCBI
16.	Alla V, Kowtharapu BS, Engelmann D, et al: E2F1 confers anticancer drug resistance by targeting ABC transporter family members and Bcl-2 via the p73/DNp73-miR-205 circuitry. Cell Cycle. 11:3067–3078. 2012. View Article : Google Scholar : PubMed/NCBI
17.	Gandellini P, Profumo V, Casamichele A, et al: miR-205 regulates basement membrane deposition in human prostate: implications for cancer development. Cell Death Differ. 19:1750–1760. 2012. View Article : Google Scholar : PubMed/NCBI
18.	Tucci P, Agostini M, Grespi F, et al: Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci USA. 109:15312–15317. 2012. View Article : Google Scholar : PubMed/NCBI
19.	Adachi R, Horiuchi S, Sakurazawa Y, Hasegawa T, Sato K and Sakamaki T: ErbB2 down-regulates microRNA-205 in breast cancer. Biochem Biophys Res Commun. 411:804–808. 2011. View Article : Google Scholar : PubMed/NCBI
20.	Bhatnagar N, Li X, Padi SK, Zhang Q, Tang MS and Guo B: Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis. 1:e1052010. View Article : Google Scholar : PubMed/NCBI
21.	Fleischmann A, Huland H, Mirlacher M, et al: Prognostic relevance of Bcl-2 overexpression in surgically treated prostate cancer is not caused by increased copy number or translocation of the gene. Prostate. 72:991–997. 2011. View Article : Google Scholar : PubMed/NCBI
22.	Cho IC, Chung HS, Cho KS, et al: Bcl-2 as a predictive factor for biochemical recurrence after radical prostatectomy: an interim analysis. Cancer Res Treat. 42:157–162. 2010. View Article : Google Scholar : PubMed/NCBI
23.	Schaefer A, Jung M, Miller K, et al: Suitable reference genes for relative quantification of miRNA expression in prostate cancer. Exp Mol Med. 42:749–758. 2010. View Article : Google Scholar : PubMed/NCBI
24.	Revelos K, Petraki C, Gregorakis A, Scorilas A, Papanastasiou P and Koutsilieris M: Immunohistochemical expression of Bcl2 is an independent predictor of time-to-biochemical failure in patients with clinically localized prostate cancer following radical prostatectomy. Anticancer Res. 25:3123–3133. 2005.
25.	Zuker M: Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 31:3406–3415. 2003. View Article : Google Scholar : PubMed/NCBI
26.	Martin MM, Buckenberger JA, Jiang J, et al: The human angiotensin II type 1 receptor +1166 A/C polymorphism attenuates microrna-155 binding. J Biol Chem. 282:24262–24269. 2007.
27.	Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP and Bartel DP: MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell. 27:91–105. 2007. View Article : Google Scholar : PubMed/NCBI
28.	Tarasov V, Jung P, Verdoodt B, et al: Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle. 6:1586–1593. 2007. View Article : Google Scholar : PubMed/NCBI
29.	Shen Y, Iqbal J, Huang JZ, Zhou G and Chan WC: BCL2 protein expression parallels its mRNA level in normal and malignant B cells. Blood. 104:2936–2939. 2004. View Article : Google Scholar : PubMed/NCBI
30.	Carvalho JR, Filipe L, Costa VL, et al: Detailed analysis of expression and promoter methylation status of apoptosis-related genes in prostate cancer. Apoptosis. 15:956–965. 2010. View Article : Google Scholar : PubMed/NCBI
31.	Gandellini P, Folini M, Longoni N, et al: miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase C epsilon. Cancer Res. 69:2287–2295. 2009. View Article : Google Scholar : PubMed/NCBI
32.	Wright JL SC, Lin DW, Kolb S, et al: Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4+3 and Gleason 3+4 tumors in a population based cohort. J Urol. 182:2702–2707. 2009.
33.	Greene SB, Gunaratne PH, Hammond SM and Rosen JM: A putative role for microRNA-205 in mammary epithelial cell progenitors. J Cell Sci. 123:606–618. 2010. View Article : Google Scholar : PubMed/NCBI
34.	Yoshino T, Shiina H, Urakami S, et al: Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res. 12:6116–6124. 2006. View Article : Google Scholar : PubMed/NCBI
35.	Colombel M, Symmans F, Gil S, et al: Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. Am J Pathol. 143:390–400. 1993.PubMed/NCBI
36.	McDonnell TJ, Troncoso P, Brisbay SM, et al: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 52:6940–6944. 1992.PubMed/NCBI
37.	Cimmino A, Calin GA, Fabbri M, et al: miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA. 102:13944–13949. 2005. View Article : Google Scholar : PubMed/NCBI
38.	Hagman Z, Larne O, Edsjo A, et al: miR-34c is down regulated in prostate cancer and exerts tumor suppressive functions. Int J Cancer. 127:2768–2776. 2010. View Article : Google Scholar : PubMed/NCBI
39.	Cole KA, Attiyeh EF, Mosse YP, et al: A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol Cancer Res. 6:735–742. 2008. View Article : Google Scholar : PubMed/NCBI
40.	Cho NY, Kim BH, Choi M, et al: Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features. J Pathol. 211:269–277. 2007. View Article : Google Scholar : PubMed/NCBI